DDInter1729 DDInter518
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Diflunisal
Diflunisal {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Cinacalcet
Cinacalcet {u} (Compound) resembles {v} (Compound) Dexfenfluramine
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) HTR2C
HTR2C {u} (Gene) is bound by {v} (Compound) Dexfenfluramine
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Sulindac {u} (Compound) binds {v} (Gene) AKR1B1
AKR1B1 {u} (Gene) regulates {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Dexfenfluramine
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) ARL4C
ARL4C {u} (Gene) is upregulated by {v} (Compound) Dexfenfluramine
Sulindac {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Fluoxetine
Fluoxetine {u} may lead to a major life threatening interaction when taken with {v} Dexfenfluramine
Sulindac {u} (Compound) binds {v} (Gene) AKR1B1
AKR1B1 {u} (Gene) regulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Dexfenfluramine
Sulindac {u} (Compound) binds {v} (Gene) PPARD
PPARD {u} (Gene) is upregulated by {v} (Compound) Pioglitazone
Pioglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexfenfluramine
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dexfenfluramine (Compound)
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Diflunisal (Compound) and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cinacalcet (Compound) and Cinacalcet (Compound) resembles Dexfenfluramine (Compound)
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by HTR2C (Gene) and HTR2C (Gene) is bound by Dexfenfluramine (Compound)
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Sulindac (Compound) binds AKR1B1 (Gene) and AKR1B1 (Gene) regulates CES1 (Gene) and CES1 (Gene) is upregulated by Dexfenfluramine (Compound)
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by ARL4C (Gene) and ARL4C (Gene) is upregulated by Dexfenfluramine (Compound)
Sulindac (Compound) binds ALB (Gene) and ALB (Gene) is bound by Fluoxetine (Compound) and Fluoxetine may lead to a major life threatening interaction when taken with Dexfenfluramine
Sulindac (Compound) binds AKR1B1 (Gene) and AKR1B1 (Gene) regulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Dexfenfluramine (Compound)
Sulindac (Compound) binds PPARD (Gene) and PPARD (Gene) is upregulated by Pioglitazone (Compound) and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine